"At-risk" generic launches refer to generic pharmaceuticals that are approved by FDA based on the review of an abbreviated new drug application (ANDA) and are subsequently launched while patent litigation is ongoing.
"At-risk" generic launches refer to generic pharmaceuticals that are approved by FDA based on the review of an abbreviated new drug application (ANDA) and are subsequently launched while patent litigation is ongoing. Launching these generics is risky because they can be pulled from the market if courts determine that patents protecting a branded reference product are violated or infringed, thus allowing the brand company to seek triple monetary damages.
The key implication of at-risk generic launches is that they create conditions of unpredictability and confusion, said Diana Papshev, PharmD, partner, InformaCeutica ( http://DrugManagementForum.com/), Yardley, Pa., at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego. "Formulary management becomes challenging in this unpredictable environment where at-risk generics might undergo market withdrawal due to the patent litigation outcomes. Uncertainty about generic product availability also creates confusion in the retail pharmacy setting. In fact, surveys show that more than 50% of retail pharmacists are uncomfortable with dispensing at-risk generics."
In the case of ANDAs submitted by generic pharmaceutical companies with a Paragraph IV certification (which basically challenge existing patents), the law grants brand manufacturers a 30-month waiting period in the form of a stay on FDA approval to pursue a generic company that may be infringing on their patent. Once litigation is initiated, companies might settle, courts may affirm contested patents, courts may find in favor of the generic companies, or the 30-month stay can expire prior to case resolution. The last two options can trigger FDA approval even if litigation is still on-going.
Implications for managed care include unpredictability of forecasting products, contract negotiations and formulary management issues, as well as market confusion.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More